Stay tuned for our LIVE OncLive News Network coverage straight from the #ASH18 conference floor! 

Dr. Houber on the De-Escalation of Treatments for Breast Cancer

Jens Huober, MD
Published: Tuesday, Jun 06, 2017



Jens Huober, MD, professor of gynecologic oncology, Ulm University Hospital, discusses the de-escalation of treatments for patients with breast cancer.

Both escalation and de-escaltation will play a role in the future of breast cancer. There are ongoing trials investigating the de-escalation of radiotherapy, explains Houber.

However, there will also need to be scenarios of escalation in patients with triple-negative breast cancer. What is currently being investigated is adding to cisplatin-based chemotherapy to increase the efficacy.
 


Jens Huober, MD, professor of gynecologic oncology, Ulm University Hospital, discusses the de-escalation of treatments for patients with breast cancer.

Both escalation and de-escaltation will play a role in the future of breast cancer. There are ongoing trials investigating the de-escalation of radiotherapy, explains Houber.

However, there will also need to be scenarios of escalation in patients with triple-negative breast cancer. What is currently being investigated is adding to cisplatin-based chemotherapy to increase the efficacy.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Miami Breast Cancer Conference®: Attendee Tumor Board OnlineNov 30, 20181.5
Community Practice Connections™: 1st Annual Paris Breast Cancer Conference™Dec 31, 20181.5
Publication Bottom Border
Border Publication
x